1	Disentangling shared genetic etiologies for kidney function and cardiovascular
2	diseases
3	Jun Qiao ^{1#} , Kaixin Yao ^{2,3#} , Yujuan Yuan ^{4,5#} , Xichen Yang ^{2,3} , Le Zhou ^{2,3} , Yinqi Long ^{2,3} ,
4	Miaoran Chen ^{2,3} , Wenjia Xie ^{2,3} , Yixuan Yang ^{2,3} , Yangpo Cao ¹ , Siim Pauklin ^{6*} , Jinguo
5	Xu ^{7*} , Yining Yang ^{4,5*} , Yuliang Feng ^{1*}
6	¹ Department of Pharmacology, Joint Laboratory of Guangdong-Hong Kong
7	Universities for Vascular Homeostasis and Diseases, School of Medicine, Southern
8	University of Science and Technology, Shenzhen, China.
9	² Department of Nephrology, Shanxi Kidney Disease Institute, Second Hospital of
10	Shanxi Medical University, Taiyuan, China.
11	³ Kidney Research Center of Shanxi Medical University, Taiyuan, China.
12	⁴ Department of Cardiology, People's Hospital of Xinjiang Uygur Autonomous Region,
13	Urumqi, China.
14	⁵ Xinjiang Key Laboratory of Cardiovascular Homeostasis and Regeneration Research,
15	Urumqi, China
16	⁶ Botnar Research Centre, Nuffield Department of Orthopaedics, Rheumatology and
17	Musculoskeletal Sciences, University of Oxford, Headington, Oxford, UK.
18	⁷ Department of Cardiovascular Surgery, First Affiliated Hospital of Anhui Medical
19	University, Hefei, China.
20	[#] These authors contributed equally to this work.
21	

22 *Correspondence to:

- 23 Siim Pauklin PhD
- 24 Group leader and CRUK Career Development Fellow
- 25 Botnar Research Centre, Nuffield Department of Orthopaedics, Rheumatology and
- 26 Musculoskeletal Sciences, University of Oxford, Headington, Oxford OX3 7LD, UK.
- 27 Tel: +44 (0)-1865226492
- 28 Email: siim.pauklin@ndorms.ox.ac.uk
- 29
- 30 Jinguo Xu, MD, PhD
- 31 Associate Professor
- 32 Department of Cardiovascular Surgery, First Affiliated Hospital of Anhui Medical
- 33 University, Hefei, Anhui, 230022, China
- 34 Tel: +86 (551)-65908735
- 35 Email: xujinguo@ahmu.edu.cn
- 36
- 37 Yining Yang MD, PhD
- 38 Professor
- 39 Department of Cardiology, People's Hospital of Xinjiang Uygur Autonomous Region,
- 40 Urumqi, Xinjiang Uygur Autonomous Region, 830000, China.
- 41 Xinjiang Key Laboratory of Cardiovascular Homeostasis and Regeneration Research,
- 42 Urumqi, Xinjiang Uygur Autonomous Region, 830000, China.
- 43 Tel:+86 (0991)-960200
- 44 Email: yangyn5126@xjrmyy.com

45

- 46 Yuliang Feng MD, PhD
- 47 Associate Professor
- 48 Department of Pharmacology, Joint Laboratory of Guangdong-Hong Kong
- 49 Universities for Vascular Homeostasis and Diseases, School of Medicine, Southern
- 50 University of Science and Technology, Shenzhen, Guangdong, 518055, China.
- 51 Tel:+86 (755)-88012564
- 52 Email: fengyl@sustech.edu.cn

53

54 Abstract

55	Cardiovascular diseases (CVDs) are the leading cause of death worldwide, with
56	chronic kidney disease (CKD) identified as a significant risk factor. CKD is primarily
57	monitored through the estimated glomerular filtration rate (eGFR), calculated using the
58	CKD-EPI equation. Although epidemiological and clinical studies have consistently
59	demonstrated strong associations between eGFR and CVDs, the genetic underpinnings
60	of this relationship remain elusive. Recent genome-wide association studies (GWAS)
61	have highlighted the polygenic nature of these conditions and identified several risk
62	loci correlating with their cross-phenotypes. Nonetheless, the extent and pattern of their
63	pleiotropic effects have yet to be fully elucidated. We analyzed the most
64	comprehensive GWAS summary statistics, involving around 7.5 million individuals, to
65	investigate the shared genetic architectures and the underlying mechanisms between
66	eGFR and CVDs, focusing on single nucleotide polymorphisms (SNPs), genes,
67	biological pathways, and proteins exhibiting pleiotropic effects. Our study identified
68	508 distinct genomic locations associated with pleiotropic effects across multiple traits,
69	involving 379 unique genes, notably L3MBTL3 (6q23.1), MMP24 (20q11.22), and
70	ABO (9q34.2). Additionally, pathways such as stem cell population maintenance and
71	the glutathione metabolism pathway were pivotal in mediating the relationships
72	between these traits. From the perspective of vertical pleiotropy, our findings suggest a
73	causal relationship between eGFR and conditions such as atrial fibrillation and venous
74	thromboembolism. These insights significantly enhance our understanding of the

- 75 genetic links between eGFR and CVDs, potentially guiding the development of novel
- therapeutic strategies and improving the clinical management of these conditions.

77

78 Keywords

- 79 Estimated glomerular filtration rate, Cardiovascular disease, Shared genetic
- 80 architectures, GWAS

81

82 Introduction

83 Cardiovascular diseases (CVDs) are the leading cause of mortality and disability globally, accounting for one-third of all deaths.¹ The American Heart Association 84 85 anticipates that by 2035, the economic impact of CVDs will escalate to approximately \$1.1 trillion. Among the diverse risk factors, chronic kidney disease (CKD) is 86 particularly significant, as it exacerbates heart disease.² CKD leads to an increased 87 88 production of reactive oxygen species (ROS) through oxidative stress, resulting in 89 endothelial dysfunction-a critical precursor to atherosclerosis and an elevated risk of cardiovascular events.³ Affecting about 9.1% of the global population, as the World 90 91 Health Organization reported in 2023, CKD is diagnosed and monitored by measuring 92 the estimated glomerular filtration rate (eGFR), utilizing the CKD-EPI equation. An eGFR below 60 mL/min/1.73 m² signifies notable kidney impairment.^{4,5} Research by 93 Go et al. has demonstrated a clear, graded association between declining eGFR and 94 increased cardiovascular events.^{6,7} Additionally, studies focusing on older adults reveal 95 that the risk of CVDs increases from 15% for those with an eGFR of 90 mL/min/1.73 96 m² to 40% for individuals at 30 mL/min/1.73 m² over three years.⁸ The Framingham 97 Heart Study supports these findings, showing that individuals with mildly reduced 98 eGFR levels (60 to 79 mL/min per 1.73 m²) face a higher risk of CVDs than those with 99 higher eGFR.⁹ These studies underscore the significance of eGFR as a robust 100 101 biomarker for assessing cardiovascular risk, highlighting its crucial role in clinical 102 practice.

Genome-wide association studies (GWAS) have identified hundreds of variants contributing to the risk of eGFR and CVDs, some of which are shared risk loci. For example, Graham and colleagues pinpointed 147 loci associated with eGFR, seven demonstrating significant co-localization with cardiovascular traits, highlighting a genetic link between eGFR and various CVD phenotypes.¹⁰ Genetic pleiotropy, where a single genetic variant influences multiple traits, is prevalent in complex human diseases, particularly in loci associated with CVDs. This pleiotropy can be vertical,

110 where a variant's effect on one trait impacts another, or horizontal, where a variant 111 independently affects several traits. Mendelian randomization (MR) analyses utilizing 112 vertical pleiotropy have estimated causal relationships between eGFR and CVDs. For example, Kelly et al. established a causal link between declining eGFR and increased 113 stroke risk,¹¹ while Geurts et al. identified a bidirectional causal relationship between 114 eGFR and atrial fibrillation (AF).^{12,13} However, recent studies suggest that eGFR does 115 not significantly affect other CVDs, such as AF, coronary artery disease (CAD), stroke, 116 117 and heart failure (HF). These inconsistencies in MR results, possibly due to residual 118 biases and unmeasured confounders, necessitate further investigation. Furthermore, the 119 study by Gong et al. highlights the role of horizontal pleiotropy in explaining the 120 common genetic architecture of human phenotypes, within the context of recent advances in genomic statistical tools.¹⁴ Despite these advances, the extent of horizontal 121 pleiotropy between eGFR and CVDs still needs to be explored, and the common 122 123 genetic mechanisms must be fully elucidated. Therefore, there is a critical need for 124 systematic research to investigate the shared genetic architectures between eGFR and 125 CVDs, to identify shared polygenic risk variants, and to explore the involvement of 126 specific molecular biological pathways.

127 In this study, we conducted an extensive analysis leveraged the latest GWAS summary statistics for European ancestry to explore the genetic associations between eGFR and 128 129 six major CVDs, including AF, CAD, Venous Thromboembolism (VTE), HF, 130 Peripheral Artery Disease (PAD), and Stroke. Firstly, the shared genetic basis is 131 determined by quantifying the overall and local genetic correlations and exploring the 132 overall genetic overlap. On this common genetic basis, in-depth research was 133 conducted on the potential genetic mechanisms underlying these traits. Regarding 134 horizontal pleiotropy, first, pleiotropy variation at the single nucleotide polymorphism 135 (SNP) level is detected, and then co-localization analysis is performed to locate 136 candidate causal variations accurately. Subsequently, position mapping and expression 137 quantitative trait loci (eQTL) mapping were used at the gene level to identify candidate 138 multi-effect genes. In addition, we conducted enrichment analysis on biological

- 139 pathways and elucidated the biological functions of genes associated with multiple
- 140 effector sites. We also investigated the potential association between plasma protein
- 141 levels and disease susceptibility and evaluated its potential as a therapeutic target.
- 142 Finally, MR analysis was conducted at the level of vertical pleiotropy, using whole
- 143 genome SNP data to estimate bidirectional causal effects while considering
- 144 confounding factors and sample overlap.In conclusion, our comprehensive analysis of
- 145 pleiotropy revealed the intricate genetic interactions between eGFR and CVDs. This
- 146 work provides a promising path for a deeper understanding of their genetic associations,
- 147 laying a solid foundation for future studies and driving new insights and targets in
- 148 prevention, early diagnosis, and personalized treatment.

149

150 Methods

151 Study Design

- 152 Figure 1 presents the workflow for this study.
- 153

154 Data selection and quality control

155 GWAS summary statistics for eGFR were sourced from the most extensive publicly 156 accessible meta-analysis to date, encompassing two primary datasets (n = 1,004,040): (i) from the CKDGen consortium and (ii) from the UK Biobank.¹⁵ Similarly, we selected 157 six major CVDs from large meta-analyses for greater statistical power and clinical 158 159 relevance. We extracted GWAS summary statistics for AF from a genome-wide 160 meta-analysis that included 60,620 cases and 970,216 controls of European ancestry 161 across six studies: The Nord-Trøndelag Health Study (HUNT), deCODE, the Michigan Genomics Initiative (MGI), DiscovEHR, UK Biobank, and the AFGen Consortium.¹⁶ 162 163 GWAS summary statistics for CAD were from a meta-analysis encompassed 181,522 164 cases and 984,168 controls of European ancestry, amalgamating data from nine studies 165 not previously included along with data from the UK Biobank and CARDIoGRAMplusC4D consortium.¹⁷ GWAS summary statistics for VTE were 166

167 obtained from a meta-analysis of seven cohorts, including the Copenhagen Hospital 168 Biobank Cardiovascular Disease Cohort (CHB-CVDC), Danish Blood Donor Study 169 (DBDS), Intermountain Healthcare, deCODE, UK Biobank, Million Veteran Program (MVP), and FinnGen, totaling 81,190 cases and 1,419,671 controls.¹⁸ GWAS summary 170 statistics for HF included data from 47,309 cases and 930,014 controls across 26 studies 171 from the Heart Failure Molecular Epidemiology for Therapeutic Targets (HERMES) 172 Consortium.¹⁹ GWAS summary statistics for PAD involved 12.086 cases and 499.548 173 controls from a genome-wide meta-analysis comprising 11 independent studies.²⁰ 174 GWAS summary statistics for Stroke were sourced from a meta-analysis by the 175 176 GIGASTROKE consortium, which included 73,652 patients and 1,234,808 control individuals.²¹ All summary statistics are based on individuals of European ancestry due 177 to the limited availability of well-powered GWAS for other ancestries. Further details 178 179 about the traits are available in eTable 1 in Supplement 1.

180

Before further analysis, we implemented rigorous quality control measures on these GWAS summary statistics by aligning them with the 1000 Genomes Project Phase 3 European population based on the hg19 genome build, removing SNPs lacking rsIDs or with duplicate rsIDs, restricting the analysis to autosomal chromosomes, and retaining only SNPs with a minor allele frequency (MAF) greater than 0.01. A total of 6,907,393 SNPs were included in the final analysis.

187

188 Genetic correlation between eGFR and CVDs

189 In order to investigate the possible shared genetic basis of eGFR and CVDs, we estimated SNP-based heritability (h^2_{SNP}) and evaluated genome-wide genetic 190 correlation (r_e) by means of cross-trait linkage disequilibrium (LD) score regression 191 (LDSC) method.²² LDSC estimates the genetic contribution to complex diseases and 192 traits by quantifying the LD between each SNP and its neighbors. Initially, we 193 performed univariate LDSC to estimate h^2_{SNP} , which reflects the proportion of 194 phenotypic variation in a trait explained by shared genetic variants. LD scores were 195 calculated for each SNP using genotypes of common SNPs within a 10 Mb window 196

197 sourced from the 1000 Genomes Project Phase 3 European population. SNPs in the 198 major histocompatibility complex (MHC) region (chromosome 6: 25-35 Mb) were 199 excluded due to their intricate LD structure. We then conducted bivariate LDSC to 200 assess the r_g between eGFR and CVDs, using regression of LD scores against the 201 product of z statistics from the respective diseases and traits. The r_g ranges from -1, 202 representing a complete negative correlation, to +1, representing a complete positive correlation, with values closer to these extremes indicating stronger correlations. The 203 204 intercept from LDSC may indicate a possible sample overlap among the GWAS data 205 sets; however, it is possible to estimate the r_g in an unbiased manner, even with 206 overlapping samples. After evaluating all pairwise r_g , we applied a Bonferroni correction for multiple comparisons, setting the significance threshold at $P < 8.33 \times 10^{-3}$ 207 208 (0.05 / 6).

209

210 In order to evaluate the biological basis of the shared genetic predisposition to eGFR 211 and CVDs, we performed stratified LDSC applied to specifically expressed genes 212 (LDSC-SEG) to identify possible enrichment of related tissue and cell types. This 213 method integrates multi-tissue gene expression data from sources like the 214 Genotype-Tissue Expression (GTEx) and Franke Lab, as well as multi-tissue chromatin 215 information from the Roadmap Epigenomics and ENCODE datasets. The GTEx 216 project provided statistics representing key tissue types and their specific expression 217 across 49 tissues using baseline models and complete genomes. Additionally, we 218 incorporated tissue-specific histone marker annotations from the Roadmap 219 Epigenomics project. This included narrow peaks for DNase Hypersensitivity, 220 H3K27ac, H3K4me1, H3K4me3, H3K9ac, and H3K36me3 chromatid. For identified 221 relevant tissues or cell types, we used the false discovery rate (FDR) method to correct 222 for each dataset, with a significance threshold of FDR < 0.05.

223

224 Genetic overlap between eGFR and CVDs

LDSC primarily measures the average genetic correlation of effect sizes for all SNPs across the genome. This approach can potentially obscure the shared genetic

227 architectures involving a mixture of concordant and discordant effect directions and 228 may fail to capture specific overlapping loci and relevant genes. To address this 229 limitation and quantify the polygenic overlap between eGFR and CVDs, we employed the causal mixture modeling approach (MiXeR).²³ Firstly, univariate MiXeR analyses 230 were performed to estimate polygenicity (i.e., the count of variants explaining 90% of 231 h_{SNP}^2) and discoverability (the proportion of phenotypic variance attributable to causal 232 variant effect sizes).²³ We used data from the 1000 Genomes Project Phase 3 European 233 population for our analyses and excluded SNPs within the structurally complex MHC 234 235 region (CHR 6: 26-35 Mb). Subsequently, bivariate MiXeR analyses were conducted to 236 ascertain the total count of trait-specific and shared causal SNPs visually represented in 237 Venn diagrams. This delineation covers four components: unique causal variants for 238 trait 1, unique for trait 2, shared causal variants, and shared non-causal variants. MiXeR 239 calculates Dice coefficient scores (ranging from 0 to 1) to gauge polygenic overlap and 240 estimates the proportion of SNPs with concordant effects within the shared genetic component. Additionally, MiXeR computes the r_g and the correlation of effect sizes 241 242 within the shared genetic component (r_{gs}). To evaluate model fit, indicative of MiXeR's 243 predictive accuracy against actual GWAS data, we constructed conditional 244 quantile-quantile (Q-Q) plots, used the Akaike Information Criterion (AIC), and 245 generated log-likelihood plots. A model-based Q-Q plot that closely aligns with the 246 actual Q-Q plot indicates strong predictive capability. A positive AIC value suggests 247 the model adequately distinguishes itself from comparative models, indicating a 248 reliable fit. Conversely, a negative AIC implies that the MiXeR model does not 249 significantly differentiate from scenarios of maximum or minimum genetic overlap, 250 rendering the genetic overlap estimate potentially unreliable.

251

252 Local genetic correlation between eGFR and CVDs

To estimate local genetic correlations (local- $r_g s$) between eGFR and CVDs within specific genomic regions and identify loci with mixed effect directions, we utilized the Local Analysis of [co]Variant Annotation (LAVA).²⁴ LAVA captures detailed patterns of shared genetic loci across individuals, revealing mixed effect directions obscured by

257 genome-wide r_g estimates due to opposing effects across genomic regions. Unlike the 258 genome-wide correlation analysis using LDSC, which considers the entire genome, 259 LAVA divides the genome into 2,495 local LD blocks and estimates r_g within each block. Differing from MiXeR's method of estimating the proportion of shared 'causal' 260 261 variants with concordant effects, LAVA identifies mixed effect directions by capturing 262 significantly correlated genetic loci. Our study began with a univariate LAVA analysis 263 to estimate local heritability for each phenotype, considering loci with p-values < 1×10^{-4} as significant genetic signals. This approach identified 425 loci for subsequent 264 bivariate tests to estimate pairwise bivariate local- r_gs across the genome. We adjusted 265 266 the p-values for local- r_{gs} based on the number of bivariate tests, setting a Bonferroni-corrected significance threshold at $P < 1.18 \times 10^{-4}$ (0.05/425). 267

268

269 Additionally, we employed Hypothesis Prioritisation for multi-trait Colocalization 270 (HyPrColoc) on genomic regions with shared risk loci across multiple phenotypes to 271 elucidate potential biological mechanisms linking traits. HyPrColoc, a Bayesian 272 approach, identifies clusters of co-localization and candidate cause variants in the same 273 genomic locus. It estimates the posterior probability (PP) of colocalization of multiple 274 traits within a single causal variant, considering PP > 0.7 as significant evidence of 275 colocalization. This method enhances our understanding of how genetic variants 276 contribute to multiple traits, offering insights into complex trait interactions.

277

278 Mendelian randomization analysis between eGFR and CVDs

279 The genetic correlation and overlap analysis explored the shared genetic foundation 280 between eGFR and CVDs; however, whether their relationship is mediated by vertical 281 or horizontal pleiotropy remains unclear. Latent Heritable Confounder Mendelian Randomization (LHC-MR)²⁵ provides valuable insights into the causal relationship 282 between eGFR and CVDs by utilizing vertical pleiotropy. This approach makes full use 283 284 of all genome-wide variations, improves statistical capacity, and corrects for sample 285 overlap, rather than just significant loci throughout the genome. Critically, LHC-MR is 286 able to distinguish between SNPs according to their co-association with a set of traits,

287 and to differentiate heritable confounding that results in r_g . This capability allows 288 LHC-MR to provide concurrent unbiased estimates of bidirectional causal and 289 confounder effects. The LHC-MR framework accommodates multiple pathways 290 through which SNPs can affect the traits, including allowing for null effects, thereby 291 enabling precise causal effect estimations. Causal estimates from LHC-MR are 292 presented as odds ratios (ORs) with corresponding 95% confidence intervals (CIs). 293 Causality is considered unidirectional if P is lower than the Bonferroni-corrected threshold $(0.05 / 6 / 2 = 4.17 \times 10^{-3})$ and the *P*-value of the effect in the opposite 294 direction is greater than 0.05. Bidirectional causality is considered if $P < 4.17 \times 10^{-3}$ in 295 296 both directions. Additionally, we employed several methods as sensitivity analyses to 297 validate the results, including the inverse variance weighted (IVW) method, the 298 weighted median, MR-Egger, simple mode, and weighted mode. These analyses help 299 confirm the robustness of the causal inferences drawn from our study.

300

301 SNP-level analysis

302 Identification of pleiotropic loci between eGFR and CVDs

In order to explore the effect of horizontal pleiotropy between eGFR and CVDs, we
used Pleiotropic Analysis under the Composite Null Hypothesis (PLACO) to clarify the

shared genetic mechanisms underlying these conditions.²⁶ PLACO identifies

306 pleiotropic loci between two traits by testing the compound null hypothesis that a locus

307 is related to either none or only one of them. This hypothesis is further subdivided into

specific sub-scenarios: (1) M00, indicating no association with any trait; (2) M10 and

M01, each indicating an association with only one of the traits; and (3) M11,

representing a pleiotropic association with both traits. This method calculates the

PLACO statistics by multiplying the Z-scores of the two traits ($Z_{trait1} \times Z_{trait2}$) while

excluding SNPs with squared Z-values above 100 to mitigate spurious signals of

313 pleiotropy. SNPs are considered to exhibit significant genome-wide pleiotropy if their

314 P_{PLACO} is less than 5×10^{-8} .

315

316 Genomic loci definition and functional analysis

317 To identify pleiotropic SNPs associated with eGFR and CVDs, we utilized the 318 Functional Mapping and Annotation of Genome-Wide Association Studies (FUMA) 319 platform. FUMA integrates data from a variety of biological databases to improve functional annotation, gene prioritization, and interactive visualization of GWAS 320 outcomes.²⁷ We calculated LD scores using the 1000 Genomes Phase III European 321 population as a reference. Firstly, independently significant SNPs achieving 322 genome-wide significance ($P < 5.0 \times 10^{-8}$ and $r^2 < 0.6$) were identified. Lead SNPs 323 were then determined based on their independence ($r^2 < 0.1$). Genomic risk sites were 324 delineated by merging lead SNPs within 500 kb of each other, allowing these sites to 325 326 contain multiple lead SNPs. The top lead SNP at each site, defined by the lowest P 327 value, was selected. Additionally, the directional impact of these sites was assessed by 328 comparing Z-scores between eGFR and CVD, providing insights into their potential 329 roles in these conditions. A GWAS site was considered novel if none of its lead, 330 independent, or candidate SNPs overlapped with SNPs previously reported in GWAS 331 meta-analyses. Using LocusZoom, we created a regional association plot with gene 332 tracks, allowing us to examine the details of the relationship between each locus. To 333 predict the functional outcomes of Top SNPs, we matched SNPs to databases 334 containing established functional annotations, including the Annotate Variation (ANNOVAR) category, Combined Annotation-Dependent Depletion (CADD) score, 335 RegulomeDB (RDB) score, and chromatin state.²⁸⁻³⁰ The CADD score is used to 336 predict the deleteriousness of SNP effects, incorporating 63 functional annotations. A 337 338 threshold of 12.37 is generally recognized as indicative of deleterious variants, and thus, 339 we filtered SNPs with a CADD score greater than 12.37 for location mapping. In order 340 to prioritize eQTL genes and explore their potential regulatory role, we used 341 RegulomeDB, which provides functional interpretation of SNPs based on curated 342 references. The RegulomeDB scoring system, ranging from 1a (most regulatory 343 potential) to 7 (least), helps evaluate the regulatory likelihood of SNPs. Additionally, 344 chromatin states were used to delineate the regulatory landscape of genomic regions, 345 with 15 classes of states predicted using 5 chromatin markers across 127 epigenomes via the ChromHMM tool.³¹ Two methods were employed to map SNPs to genes: (i) 346

positional mapping, which assigns SNPs to genes based on their physical proximity (within a 10kb window) to known protein-coding genes in the human reference assembly, and (ii) eQTL mapping, which links SNPs to genes based on significant eQTL associations, where allelic variations in an SNP correlate with variations in gene expression levels, as identified using the GTEx database. This approach improves our understanding of the genetic structure by linking SNPs to potential functional outcomes.

354

355 Colocalization analysis

356 For FUMA-annotated pleiotropic loci, we performed a Bayesian colocalization 357 analysis to identify potential common causal variations between trait pairs. COLOC employs a Bayesian framework to calculate the PP of five distinct hypotheses 358 concerning shared causal variation within a genomic region.³² These hypotheses assess 359 whether one or both traits share causal variations at a specific locus. Specifically, the 360 361 hypotheses are as follows: i) PPH0: Neither trait has causal variation at the locus; ii) 362 PPH1: Only the first trait has causal variation at the locus; iii) PPH2: Only the second 363 trait has causal variation at the locus; iv) PPH3: Each trait has a different causal 364 variation within the locus; v) PPH4: Both traits share a causal variation within the locus.³³ The SNP exhibiting the highest PPH4 within the locus is identified as the 365 366 candidate causal variant. Loci are considered colocalized if the PPH4 exceeds 0.7, indicating a strong likelihood that the locus harbors shared causal variations for the 367 368 traits under study.

- 369
- 370

371 Gene-level analysis using MAGMA, eMAGMA and TWAS

To identify candidate pleiotropic genes further, we conducted Multi-marker Analysis of GenoMic Annotation (MAGMA) based on results from PLACO and individual GWAS. MAGMA uses the SNP average model within the multi-regression framework to derive *P* values, and to estimate the association of the gene, and to adjust for factors such as the size of the gene, the number of SNP for each gene, and the LD between markers.³⁴

377 Our analysis referenced the 1000 Genomes Project Phase 3 European population and 378 used the Genome Reference Consortium Human Build 37 (hg19) for SNP locations and 379 gene annotations. We analyzed 17,636 protein-coding genes on the MAGMA software 380 website, focusing on genes containing at least ten SNPs to ensure computational 381 stability. Gene based testing involves extending 10kb upstream and downstream of the 382 gene transcription start and end sites. Because of their complicated LD patterns, we 383 ruled out MHC regions (chr6: 25 - 35 Mb). Strict Bonferroni correction was used for 384 adjustment for multiple trials, and in the MAGMA analysis based on the PLACO results, a significant threshold of $P < 4.23 \times 10^{-7}$ (0.05 / 17636 / 6) was established. 385

386

387 The inherent limitations of MAGMA, which assigns SNPs based solely on proximity to 388 genes without accounting for functional associations such as gene regulation, can 389 hinder its effectiveness in elucidating the underlying mechanisms of genetic variants. 390 To overcome this and delve deeper into the functional implications of genetic variants 391 associated with eGFR and CVDs, we employed the EQTL-informed MAGMA (E-MAGMA).³⁵ Operating within the same statistical framework as MAGMA, 392 393 E-MAGMA uses a multi-principal component linear regression model to leverage 394 tissue-specific eQTL data from multiple sources, aiming to identify potential causal 395 genes for phenotypic traits. Our study utilized eQTL data from 47 tissues, enriched for 396 differentially expressed genes in tissues as provided by the Genotype-Tissue 397 Expression Project version 8 (GTEx v8), and referenced the 1000 Genomes Project 398 Phase 3 European population. To mitigate potential confounding effects from the broad 399 range of tissues, we focused on 11 specific tissues that were identified by LDSC-SEG 400 analysis, including arterial, adipose, cardiac, whole blood, liver, EBV-transformed 401 lymphocytes, and kidney tissues. We excluded kidney tissue from our analysis due to 402 the absence of reference in E-MAGMA. We applied Bonferroni-adjusted p-value 403 thresholds to accommodate multiple testing, calculated based on the number of genes 404 analyzed in E-MAGMA and the number of statistically significant trait pairs tested. For example, the threshold for subcutaneous fat was defined as $P < 8.67 \times 10^{-7} (0.05 / 9.603)$ 405 406 / 6).

407

408	We conducted the Transcriptome-wide Association Study (TWAS) using single-trait
409	GWAS results to explore the tissue specific gene expression correlation between eGFR
410	and CVDs. TWAS combines eQTL and summary association statistics from large scale
411	GWAS to identify genes that are associated with complex traits. ³⁶ For gene expression
412	prediction, we utilized the FUSION tool with default settings, employing various
413	methods, including best linear unbiased prediction (BLUP), Bayesian sparse linear
414	mixed model (BSLMM), least absolute shrinkage and selection operator (LASSO),
415	elastic net (ENET), and Top SNP, which were used to estimate the cis-genetic
416	component of tissue-specific gene expression. We selected the most effective predictive
417	model to determine gene expression weights and used GWAS summary statistics to
418	conduct the TWAS. In addition, we used the Bonferroni correction to adjust for
419	multiple comparisons between the different tissue types analyzed.

420

421 Pathway-level analysis using MAGMA and Metascape

422 We conducted a MAGMA gene set analysis to elucidate the biological functions of 423 genes exhibiting pleiotropic effects on eGFR and CVDs. This analysis employs a 424 competitive gene set framework to assess whether specific gene sets are more strongly 425 associated with a particular phenotype than the broader genomic background. Our 426 approach integrates gene definitions and their respective signals using MAGMA's 427 gene-based multi-marker method. The analyzed gene set is derived from Gene 428 Ontology (GO) and Reactome pathways, as listed in the Molecular Feature Database 429 (MSigDB v7.5). The significance threshold was set to P < 0.05 / (7744 + 1654) / 6, 430 adjusted for the number of GO and Reactome pathways, as well as the number of trait 431 pairs analysed. To elucidate the biological processes and signaling pathways associated 432 with eGFR and CVDs, we conducted Metascape analysis on the overlapping genes 433 identified by MAGMA and EMAGMA. Metascape provides comprehensive annotation of gene and protein, enrichment analysis, and protein-protein interaction networks, 434 which can help to better understand the functions of genes.³⁷ We used Metascape to 435 perform GO annotation and Reactome enrichment analysis, which utilizes the 436

437 hypergeometric test to identify significant ontology terms. The GO resource offers a 438 framework and concepts to describe gene product functions across all organisms, while 439 the Reactome knowledgebase details cellular processes, such as signaling, transport, 440 DNA replication, and metabolism, as ordered networks of molecular transformations. 441 Pathways with a *p*-value < 0.01 were considered significant.

442

443 Proteome-wide Mendelian Randomization analysis using SMR

To investigate potential associations between plasma protein levels and disease 444 445 susceptibility, we employed Summary data-based Mendelian Randomization (SMR). 446 This analysis integrated plasma protein quantitative trait locus (pQTL) summary 447 statistics from the UK Biobank Pharmaceutical Proteomics Project (UKB-PPP) with 448 GWAS summary statistics for various diseases. The UKB-PPP data, derived from the 449 Olink proteomics platform, includes genetic associations for 2,940 plasma proteins 450 across a cohort of 34,557 Europeans. In this context, cis-pQTLs are defined as SNPs 451 located in the 1Mb window surrounding the transcription start site (TSS) of each 452 protein. For SMR analysis, we only took into account the cis-pQTLs related to plasma protein levels at the genome-wide significance threshold ($P < 5 \times 10^{-8}$). SMR, a method 453 454 that utilizes summary-level data, assesses potential causal relationships between 455 exposures (e.g., plasma protein levels) and outcomes (e.g., traits or diseases). In order 456 to distinguish between pleiotropy and linkage in the cis-pQTL region, we tested 457 multiple SNPs using the heterogeneity of instrument-dependent (HEIDI) method. 458 Results indicating pleiotropy (HEIDI test P < 0.01) were excluded from further analysis. 459 In recognition of the limitations of single-SNP analyses, we also performed a 460 sensitivity analysis using a multi-SNP-SMR test, with a P value of < 0.05 being 461 significant. A Bonferroni correction was applied to the number of unique proteins to be analyzed, and a significance threshold was set at $P < 3.65 \times 10^{-6} (0.05 / 1958 / 7)$. 462 Additionally, we performed COLOC analysis to determine if the same causal variation 463 464 is responsible for the association of protein levels with disease phenotype. The PP.H4 >465 0.7 for shared causal variants indicates significant colocalization of GWAS and pQTL.

467 **Result**

468 Genome-wide genetic correlation between eGFR and CVDs

469 After implementing stringent quality control, we utilized LDSC to assess h^2_{SNP} and genome-wide r_g between eGFR and CVDs. We used univariate LDSC to estimate h_{SNP}^2 470 for eGFR and each CVD. The SNP heritability estimate was highest for eGFR $(h_{SNP}^2 =$ 471 472 0.0708, SE = 0.0036). Among these CVDs, heritability estimates ranged from 0.0060 473 for Stroke, the lowest (SE = 0.0005), to 0.0324 for CAD, the highest (SE = 0.0019) 474 (Supplementary Fig. 1a and Supplementary Table 2a).We then conducted bivariate LDSC analysis to explore the r_g between eGFR and CVDs. This revealed significant 475 476 negative r_g for two trait pairs: eGFR and Stroke ($r_g = -0.0985$, SE = 0.0309) and eGFR and VTE ($r_g = -0.0783$, SE = 0.0238), both surpassing the Bonferroni-corrected 477 significance threshold ($P < 8.33 \times 10^{-3}$) (Supplementary Fig. 1b and Supplementary 478 479 Table 2b). However, no significant r_g was found between eGFR and AF, CAD, HF, or 480 PAD.

481

482 Polygenic overlap and local genetic correlation between eGFR and CVDs

483 Nevertheless, previously described r_g may underestimate the genetic overlap between 484 eGFR and CVDs. The fact that there is no significant r_g does not necessarily mean that 485 there is no common genetic component among these traits. Indeed, the r_g measure does 486 not distinguish between mixtures of concordant and discordant genetic effects and a 487 true absence of genetic overlap. To address this limitation and more comprehensively 488 elucidate the shared genetic underpinnings of complex polygenic features, we 489 employed advanced analytical tools, MiXeR and LAVA, specifically designed to 490 provide more detailed insights into genetic architectures that traditional analyses might 491 obscure.

492

We conducted MiXeR analyses to quantify the polygenic genetic overlap between eGFR and CVDs, accounting for mixed effect directions. Initially, univariate MiXeR analyses estimated that approximately 2,044 variants (SD = 111) influence eGFR. Among the CVDs, HF had the highest polygenicity, with 2,286 'causal' variants

accounting for 90% of HF h_{SNP}^2 (SD = 215), followed by CAD with 1,431 variants (SD 497 498 = 311), and stroke with 1,039 variants (SD = 120) (Supplementary Table 3a). 499 Subsequently, bivariate analyses revealed significant polygenic overlap between eGFR 500 and these CVDs, with Dice coefficients ranging from 0.024 to 0.457 (Fig. 2a, 501 Supplementary Fig. 2, Supplementary Table 3b). Notably, eGFR displayed a moderate genetic overlap with diseases like CAD (Dice = 0.457), HF (Dice = 0.39), and stroke 502 503 (Dice = 0.35). Among these, the eGFR-HF pair possessed the highest number of shared 504 'causal' variants (841, SD=151), accounting for substantial proportions of variants 505 affecting each condition (41.1% for eGFR and 36.8% for HF), suggesting highly 506 similar genetic architectures between these two traits. However, the genetic correlation $(4.78 \times 10^{-4}, \text{SD}=9.83\text{E}-3)$ and the correlation coefficients of genetic risk $(9.62 \times 10^{-4}, \text{SD}=9.83\text{E}-3)$ 507 SD=0.024) between eGFR and HF were notably weak. This extensive genetic overlap, 508 coupled with weak r_g , highlights the existence of mixed effects, as demonstrated by the 509 510 proportion of shared 'causal' variants with consistent effects (0.50, SD = 0.007). A similar relationship was observed between eGFR-CAD and eGFR-Stroke, with the r_g 511 and r_{gs} (r_{g} = -0.098; r_{gs} = -0.269) of eGFR-Stroke consistent with their 512 513 LDSC-estimated significant negative genetic correlations. Compared to diseases with 514 lower polygenicity, such as AF, VTE, and PAD, eGFR is characterized as a highly 515 polygenic trait, leading to significant disparities in the number of shared and unique 516 'causal' variants. For instance, the eGFR-VTE pair demonstrated mild genetic overlap 517 (Dice = 0.177) with 211 shared variants (SD = 83), accounting for 10.3% of eGFR's and 66.2% of VTE's heritability, and exhibited the highest genetic risk correlation ($r_g =$ 518 -0.115, SD = 0.007). Conversely, the eGFR-PAD pair had the fewest shared variants (28, 519 520 SD = 15), but the shared genetic components showed the strongest correlation (r_{gs} = 521 0.567, SD = 0.351), indicating that while many eGFR-associated variants do not 522 influence PAD, those that do have highly similar effects (Supplementary Fig. 2).

523

LAVA, which calculates local- $r_g s$, was employed to explore further the relationships between eGFR and CVDs, revealing mixed effect directions. First, univariate analyses were conducted to identify heritable regions, filtering out loci devoid of univariate

527 heritability (Supplementary Table 4), leading to 425 bivariate tests. While no 528 significant genome-wide r_g emerged between eGFR and diseases such as AF, CAD, HF, or PAD, LAVA identified specific regions with significant local- r_{gs} (P < 0.05, Fig.2b 529 530 and Supplementary Table 5). This was particularly notable between eGFR and CAD, 531 where 27 positively and 28 negatively correlated regions were found, suggesting that 532 non-significant genome-wide the overall correlation could result from counterbalancing local effects. Similarly, mixed effects were observed with other 533 534 diseases: eGFR and AF exhibited 17 positive and 18 negative regions, HF showed 5 535 positive and 4 negative regions, and PAD had an equal number of positive and negative regions (4 each). Contrary to these, eGFR and VTE displayed more negatively 536 537 correlated regions (12 positive / 23 negative), aligning with the negative genome-wide 538 correlations estimated by LDSC. However, the findings for eGFR and Stroke, which 539 presented more positively than negatively correlated regions, did not consistently align 540 with the negative r_g estimated by LDSC, though 5 negatively correlated regions were 541 still identified. After applying the Bonferroni correction, 36 genetic regions showed 542 significant local- r_{gs} . Notably, three genetic regions were linked to multiple trait pairs: 543 LD block 96 on chromosome 1 was associated with both eGFR-CAD and eGFR-VTE; 544 LD blocks 673 on chromosome 4 and 1057 on chromosome 6 exhibited correlations 545 between eGFR-AF and eGFR-CAD. Further analysis using HyPrColoc identified 546 shared causal variants, with SNP rs12740374 in LD block 96 showing strong co-localization evidence of influencing eGFR-VTE and CAD with a PP greater than 547 548 0.7.

549

In summary, we systematically quantified the genetic overlap between eGFR and six major CVDs using MiexR and LAVA, going beyond simple genome-wide r_g . These analyses highlighted significant shared genetic bases between eGFR and the CVDs, which were not apparent from traditional genome-wide studies alone. Building on these findings, we performed further pleiotropy analysis to delve deeper into the molecular mechanisms underlying these trait pairs.

556

557 Causal effects identified between eGFR and CVDs

558 Based on the above-mentioned common genetic basis between eGFR and CVDs, we 559 implemented multiple pleiotropy methods to reveal the potential mechanisms of 560 vertical or horizontal pleiotropy. Among them, in terms of vertical pleiotropy, we used 561 LHC-MR technology to study causal relationships while controlling bias and 562 confounding factors. Our analysis found that AF had a significant reverse causal effect 563 on eGFR (OR: 0.806; 95% CI = 0.720 to 0.903), which suggests that the presence of AF 564 may reduce eGFR. In addition, we observed another pair of significant negative causal 565 relationships, indicating that an increase in eGFR would reduce the risk of VTE (OR = 566 (0.931; 95% CI = 0.899 to 0.964) (Fig. 3, Supplementary Table 6a). These findings were 567 confirmed by the results of the IVW method. In summary, our MR study provides 568 strong evidence for the causal relationship between AF and eGFR and between eGFR and VTE (Supplementary Fig. 5, Supplementary Table 6b). However, it must be 569 570 recognized that vertical pleiotropy alone cannot fully explain the common genetic basis between eGFR and CVDs. 571

572

573 Pleiotropic genomic loci identified between eGFR and CVDs

574 Given the extensive genome-wide genetic overlap, we further tested pleiotropic SNPs between eGFR and CVDs by PLACO, and a total of 20,073 SNPs ($P < 5 \times 10^{-8}$) were 575 576 identified as significant pleiotropic variants. FUMA aggregated these SNPs into 508 loci, involving 226 unique chromosomal regions, of which 32 loci appeared in over 50% 577 578 of trait pairs (Fig. 4, Supplementary Fig 6, Supplementary Table 7). Notably, loci such as 6q25.3 (SLC22A1), 8p23.1 (BLK), 9q34.2 (ABO), and 6p21.1 (CRIP3) showed 579 overlap across all six trait pairs, while 12q24.12 (ALDH2) appeared in five. These 580 581 broad pleiotropic effects are exemplified by the common variants at 6p21.1, which are 582 associated with both polycystic kidney disease and stroke, and by 12q24.12, a locus 583 significant for CAD and stroke. Interestingly, 24 pleiotropic loci had not been reported 584 in previous eGFR and CVD studies, which reported 81 and 364 loci, respectively. 585 Targeted analysis within the 508 pleiotropic loci revealed that 139 top SNPs (27.4%) 586 indicated an increased risk for these traits, while 118 (23.2%) indicated a reduced risk.

587 The remaining 251 top SNPs (49.4%) showed discordant associations, highlighting 588 potential contrasting biological mechanisms. Functional annotation using FUMA 589 identified that 330 SNPs (65.0%) were intronic variants, 127 (25.0%) were intergenic, 590 and 21 (4.1%) were exonic, including 14 mRNA and 7 non-coding RNA exon variants. 591 Moreover, 40 SNPs in these risk loci, including rs34312154 with the highest CADD 592 score of 31, may be potentially harmful, affecting genes like *HOXB1* to *HOXB8*. 593 Additionally, 58 SNPs identified by RegulomeDB as potentially affecting transcription 594 factor binding underscore the regulatory significance of these findings, with rs4918003 595 showing the most potent evidence of regulatory potential (RDB: 1b). 596

597 Further analysis of co-localization at 508 identified loci revealed that 74 loci (14.6%) 598 exhibit high PP (PPH4 > 0.7), indicating strong evidence of shared genetic signals (Fig. 599 4, Supplementary Fig. 7, Supplementary Table 7). Of these, 71 top SNPs were 600 identified as candidate common pathogenic variants. Notably, the 1p13.3 locus showed 601 significant pleiotropy, influencing the trait pairs of eGFR-CAD, eGFR-VTE, and 602 eGFR-HF, with PP.H4 values ranging from 0.956 to 0.998. Subsequent HyPrColoc 603 analysis identified rs660240 in the CELSR2 gene at this locus as exhibiting strong 604 co-localization for both eGFR and HF and eGFR and VTE, with PP exceeding 0.7. 605

606 Identification of pleiotropic genes between eGFR and CVDs

607 We used MAGMA analysis to convert the SNP level signals of identified eGFR-CVDs 608 into gene level signals, focusing on potential pleiotropy within or overlapping 508 609 pleiotropic loci. This analysis identified 802 significant pleiotropic genes, with 579 610 being unique. Notably, 379 genes were implicated in more than one trait pair, providing 611 robust statistical evidence for shared genetic inheritance across diverse traits (Fig. 5, 612 Supplementary Table 11). Specific genes such as ATXN2 (located at 12q24.12) 613 significantly impacted five trait pairs. Additionally, genes including ABO (9q34.2), 614 BRAP (12q24.12), SH2B3 (12q24.12), L3MBTL3 (6q23.1), MMP24 (19q13.32), 615 MRPS21 (1q21.2), and PRPF3 (1q21.2) were significant across four trait pairs,

616 underscoring their pivotal roles in these genetic networks. Remarkably, the 12q24.12 617 locus, home to ATXN2, BRAP, and SH2B3, is critical in assessing genetic risks for hypertension³⁸ and CKD, with ATXN2 linked to myocardial infarction, renal function, 618 and hypertension.³⁹ Among the genes identified, 118 were not previously explored in 619 eGFR studies, and 410 were new to CVD research, highlighting significant novel 620 findings. Positional mapping in FUMA confirmed 97.88% of these risk genes identified 621 622 by MAGMA, further solidifying the evidence for a shared genetic framework across 623 these trait pairs (Supplementary Table 9).

624

625 We employed the LDSC-SEG method to perform tissue-specific genetic analysis,

626 identifying distinct tissue associations for each trait. The analysis revealed significant

627 gene expression enrichment for eGFR in the renal cortex and liver tissues. Similarly,

AF showed considerable enrichment in the atrial appendage and cardiac left ventricular

tissues, while CAD was significantly enriched in the aorta, coronary artery, and tibial

artery tissues, with all exceeding an FDR threshold of 0.05. Subsequent LDSC-SEG

631 chromatin analysis corroborated these findings, enhancing the resolution by detecting

significant tissue chromatin signals associated with eGFR, AF, and CAD traits

633 (Supplementary Fig. 3, Supplementary Table 14).

634

635 We conducted E-MAGMA analysis on ten related tissues using tissue-specific eQTL information, which identified 1,276 pleiotropic genes that remained significant after 636 637 Bonferroni correction, showing strong enrichment in at least one of the analyzed tissues 638 (Supplementary Table 15). Particularly noteworthy, 26 genes were prevalent in over 50% 639 of trait pairs, with KAT5 and PROCR appearing in five trait pairs each and BLK and 640 *SLC22A1* in four. *KAT5*, or lysine acetyltransferase 5, serves a dual role; it regulates the 641 level of acetylation of target proteins, affecting the expression of inflammation related 642 genes and the intensity of inflammatory responses. This regulatory function is crucial, as abnormal expression or dysfunction of KAT5 can elevate cardiovascular disease risks 643 by affecting the inflammatory pathway.⁴⁰ Additionally, *KAT5* acts as a DNA repair 644 factor, vital for preventing ischemic acute kidney injury (AKI), primarily by regulating 645

glomerular filtration.⁴¹ Therefore, the normal function and activity of *KAT5* are critical 646 647 in preventing or alleviating AKI and indirectly maintaining or enhancing eGFR levels. 648 We also performed the TWAS to assess the tissue specificity of pleiotropic genes for 649 each trait, leading to the discovery of 354 new genes associated with eGFR and 142 650 new genes related to various CVDs (Supplementary Table 16). Furthering our 651 investigation, we utilized FUMA for eQTL mapping, identifing 2,049 genes, of which 652 71.40% were confirmed by our analysis to be associated with the traits under study 653 (Supplementary Table 9).

654

655 MAGMA and E-MAGMA analyses have jointly identified 424 pleiotropic genes, 656 including 314 unique ones, shedding light on the common mechanisms underlying 657 various trait pairs (Supplementary Table 11). Notably, 76 of these genes recur across 658 multiple trait pairs, with genes such as MMP24, L3MBTL3, and ABO being prominent 659 in half or more of the analyzed traits. Specific genes like ABO (9q34.13), PROCR 660 (20q11.22), BLK (8p23.1), ALDH2 (12q21.31), and SLC22A1 (6q25.3) each featured in 661 three different trait pairs, highlighting their significant roles in multiple pathologies. 662 For instance, L3MBTL3 has been implicated in renal dysfunction and cardiovascular 663 pathogenesis, illustrating the interconnectedness of renal and cardiovascular systems. 664 *MMP24*'s dysregulated expression, associated with renal tubular atrophy and diabetic 665 nephropathy (DN), may contribute to structural and functional kidney impairments that 666 exacerbate cardiovascular risk. In addition, the ABO gene, which is associated with 667 changes in von Willebrand factor (VWF) plasma levels, plays a key role in regulating 668 platelet function and atherosclerosis, thus affecting the severity of CAD. While the 669 precise mechanisms connecting ABO genes to eGFR remain elusive, their association 670 with conditions like type 2 diabetes (T2D) and hypertension, which are main risk factors for CKD, likely impacts eGFR.⁴² 671

672

673 Shared biological mechanisms between eGFR and CVDs

674 We employed the MAGMA algorithm to assess pathway enrichment among the

identified genes, setting a stringent Bonferroni-corrected threshold ($P < 8.87 \times 10^{-7}$). 675 676 This analysis revealed 78 significantly enriched pathways, comprising 73 Gene 677 Ontology Biological Process (GO BP) terms and 5 Reactome gene set pathways, 678 indicative of key biological processes (Supplementary Table 17a). Notably, pathways 679 such as the positive regulation of macromolecule biosynthetic processes, transcription 680 by RNA polymerase II, and RNA metabolic processes were enriched in half or more of 681 the trait pairs, highlighting their crucial roles in the regulation of core biological 682 processes that contribute to the development of the studied traits.

683

Further analysis of pathway enrichment for overlapping genes, identified in multiple 684 685 trait pairs from MAGMA and E-MAGMA analyses, was conducted using the 686 Metascape website (Supplementary Table 17b). This analysis pinpointed 16 687 significantly enriched pathways predominantly involved in regulating biosynthetic and 688 metabolic processes, lipid metabolism, and receptor signal transduction. The pathways 689 related to glutathione breakdown and stem cell maintenance were critical and had 690 profound implications for eGFR and CVDs. The antioxidant and anti-inflammatory 691 properties of glutathione are essential for cardiovascular protection. However, its 692 degradation may elevate the risk of CVDs through mechanisms linked to renal 693 insufficiency. Moreover, the protective roles of endothelial progenitor cells (EPC) and 694 stem cell factor (SCF) within the kidney are critical for maintaining eGFR and CVDs 695 health, implying that diminished activity in these pathways could adversely affect renal 696 and cardiovascular systems.

697

698 Proteome-wide Mendelian Randomization analysis for eGFR and CVDs

We conducted a SMR analysis utilizing GWAS summary data for eGFR, six major CVDs, and plasma protein pQTLs. This analysis identified 78 risk proteins, 32 linked to eGFR and 46 to CVDs, validated through HEIDI evaluation (P > 0.01), multiple SNP-SMR sensitivity analysis (P < 0.05), and Bonferroni corrections ($P_{SMR} < 0.05$ / (1958×7)). Subsequently, we investigated potential pleiotropic effects within specific eGFR-CVD pairs, identifying three signature pairs that contain pleiotropic proteins

705 (Supplementary Table 18). Notably, CELSR2 was common between eGFR-CAD and 706 eGFR-VTE, while FGF5 linked eGFR-AF and eGFR-CAD. Additionally, a 707 colocalization analysis of these 78 proteins sought to identify common pathogenic 708 variants associated with specific eGFR or CVDs signatures. This analysis showed 709 strong evidence of colocalization for 49 proteins (41 unique), with 17 proteins associated with eGFR and 32 with CVDs. Proteins such as CELSR2 and FGF5, 710 711 emphasized in the SMR analysis, displayed strong evidence of colocalization across 712 three identified signature pairs, underscoring a shared pathogenic pathway across these 713 conditions.

714

715 Discussion

716 In this study, a comprehensive genome-wide pleiotropy analysis was carried out to 717 investigate the genetic correlation and overlap between eGFR and CVDs, uncovering a 718 complex shared genetic foundation. Our detailed investigations identified key 719 pleiotropic loci and genes, including L3MBTL3, MMP24, and ABO, and illuminated 720 crucial biological pathways such as stem cell population maintenance and glutathione 721 metabolism. Additionally, using MR analysis, we indicated a causal relationship 722 between eGFR and VTE, as well as between AF and eGFR. Collectively, the results 723 provide a better understanding of the shared genetic etiology and biological 724 mechanisms that underlie the relationship between eGFR and CVDs, opening new 725 avenues for targeted therapeutic strategies and further research.

726

727 Our analysis probed the shared genetic architectures of eGFR and six major CVDs 728 using complementary genetic tools—LDSC, MiXeR, and LAVA—to reveal extensive 729 shared genetic bases across all trait pairs. LDSC highlighted significant negative global 730 r_g between eGFR and VTE and Stroke, contrasting with previous studies that reported 731 no significant associations. This underscores the advantage of our approach and the 732 benefits of a larger sample size. Despite the absence of significant global correlations 733 for certain traits, MiXeR identified substantial overlap for CAD, HF, and AF with 734 eGFR, indicating mixed effect directions even when global correlations are not evident.

735 LAVA provided further insights into local- r_{gs} , revealing mixed effect directions not 736 apparent from genome-wide estimates, such as those observed between eGFR and 737 CAD, which exhibited both positively and negatively correlated loci. This suggests a 738 more nuanced genetic relationship than previously recognized. Moreover, employing 739 bivariate MiXeR revealed extensive genetic overlap between eGFR and CAD, supported by LAVA's local- r_{gs} , highlighting concordant and discordant effect 740 741 directions. Our comprehensive analysis confirms the shared genetic foundations 742 between eGFR and various CVDs, indicating multiple common genetic variants 743 influencing critical biological pathways.

744

745 Our findings elucidate the shared genetic bases between eGFR and CVDs, attributable 746 to both horizontal pleiotropy and direct causal mechanisms (vertical pleiotropy). Our 747 MR analysis effectively separated potential causal effects from other genetic influences. 748 Notably, the LHC-MR results identified a reverse causal relationship of eGFR on VTE, a finding supported by Yuan et al.⁴³ This causal relationship is likely driven by impaired 749 750 kidney function, which increases coagulation factors and decreases endogenous 751 anticoagulants, collectively promoting thrombus formation. Additionally, our analysis 752 indicates a potential causal influence of AF on eGFR, aligning with previous studies that suggest AF can lead to renal impairments via mechanisms such as 753 thromboembolism and reduced renal microvascular blood flow.^{12,44} However, our 754 analysis did not establish causal relationships for other trait pairs, suggesting that while 755 756 genetic overlaps between eGFR and CVDs are partially driven by causality, the 757 complexity of these relationships varies across different conditions.

758

Our cross-trait meta-analysis has identified many genome-wide significant pleiotropic loci associated with eGFR and CVDs. Notably, loci such as 8p23.1 (*BLK*) and 6q25.3 (*SLC22A1*) demonstrated significance across six trait pairs, while others like 12q24.12 (*ALDH2*) and 20q11.22 (*PROCR*) were significant in over 50% of the trait pairs. Specifically, the BLK gene at 8p23.1 enhances insulin synthesis and secretion, linking it to CKD symptoms and complications in nephropathy and diabetes by increasing the

production of pro-inflammatory cytokines. BLK is also identified as a susceptibility 765 gene for Kawasaki disease,⁴⁵ a systemic vasculitis that can impact coronary arteries and 766 increase CVDs risks.⁴⁶ Furthermore, the locus *SLC22A1* at 6q25.3 is associated with 767 DN, a severe complication of diabetes characterized by persistent albuminuria, 768 declining eGFR, and elevated arterial blood pressure, which elevates the risk for CVDs 769 and cerebrovascular diseases.⁴⁷ The role of this locus in hypertension underscores its 770 potential as a mediator of underlying disease risks. The consistency of effect alleles in 771 772 nearly half of the significant SNPs for both eGFR and CVD supports a positive association between these conditions and provides insights into their complex r_{e} . 773

774

Our analysis has identified several key pleiotropic genes in over 50% of the trait pairs, 775 including L3MBTL3 (6q23.1), MMP24 (20q11.22), and ABO (9q34.2). For example, 776 777 L3MBTL3 significantly influences the risk of coronary heart disease (CHD) by 778 modulating adipogenesis, the process of fat cell differentiation. Dysfunctional adipose 779 tissue can lead to ectopic fat accumulation, which promotes insulin resistance and other 780 metabolic disorders, escalating the risk for obesity-related CHD. These metabolic 781 disturbances further amplify the risk of ischemic stroke by intensifying common risk 782 factors (such as hypertension and diabetes). Although L3MBTL3's expression in the 783 kidney is documented, the specific mechanisms by which it affects renal function and 784 structure remain to be fully explored. Matrix metalloproteinase-24 (MMP24) plays a 785 key role in extracellular matrix degradation, and is linked with renal tubular atrophy and the severity of alcohol-induced renal injury and fibrosis. Dysregulated MMP24 786 787 expression detrimentally impacts both renal and cardiovascular health. In DN, MMP24 is implicated in abnormal extracellular matrix accumulation, leading to significant 788 damage to the glomeruli and renal tubules and indirectly impacting eGFR.⁴⁸ Given the 789 close association of DN with T2D, a prominent risk factor for CVDs, MMP24's role in 790 DN could indirectly heighten the risk of CVDs.⁴⁹ The ABO gene, vital for determining 791 blood group phenotypes, also affects crucial hemostatic factors such as VWF and factor 792 793 VIII (FVIII), which are essential for platelet adhesion at injury sites. Individuals with non-O blood types generally exhibit higher VWF levels and are more susceptible to 794

795 VTE.⁵⁰ In addition, researchers have discovered a new connection between *ABO* and 796 primary glomerulonephritis, especially IgA nephropathy, where certain blood groups 797 are linked to an increased risk of renal function decline.⁵¹ These findings highlight the 798 complex interaction of genetics with the pathophysiology of renal and CVDs, which 799 provides a strong basis for further study of the mechanisms and risks associated with 800 genetic diseases.

801

802 Our study also examines the role of shared genetic determinants in two critical 803 biological pathways, including stem cell population maintenance and glutathione 804 catabolism, and their implications for kidney function and cardiovascular health. In the stem cell maintenance pathway, *MMP24*⁵², *PSRC1*⁵³, and *CHMP1A*⁵⁴ play pivotal roles 805 by regulating the stem cell cycle, ensuring cellular quiescence, and preventing 806 807 premature differentiation, respectively. These molecular actions are crucial for 808 promoting tubular cell growth and enhancing renal function, mainly through the 809 secretion of regenerative factors such as bone morphogenetic protein-7 and hepatocyte growth factor.⁵⁵ The effectiveness of stem cell therapy in heart repair, particularly in 810 811 those with elevated levels of inflammation, further underscores the importance of robust stem cells for optimal cardiovascular and renal outcomes. In the glutathione 812 pathway, DPEP1⁵⁶, ORMDL3, MRPS21, and CPS1^{57,58} are crucial for maintaining 813 cellular redox balance and defending against oxidative stress, and they are vital for 814 stroke prevention and kidney function maintenance.^{59,60} Variations in kidney function, 815 reflected by changes in eGFR, can significantly affect glutathione turnover and its 816 protective roles, directly linking renal and cardiovascular health.⁶¹ Our findings suggest 817 818 that targeted modulation of these key genes could significantly enhance kidney and 819 heart repair and regeneration, thus improving eGFR and decreasing the risk of CVDs. 820

Our study has some limitations. Firstly, the variation in sample sizes across disorders, from 511,634 cases for PAD to 1,500,861 for VTE, restricted our ability to detect pleiotropic effects in less-represented diseases. Future studies with larger, more balanced samples will likely improve our capacity to discern these effects more

825 precisely. Additionally, including subjects with concurrent eGFR abnormalities and 826 CVDs may have introduced bias in our assessment of genetic overlap between these 827 conditions. Our analysis focused on shared genetic variants, excluding rare mutations 828 that could further elucidate the complex genetic relationships involved. Moreover, the 829 concentration on individuals of European ancestry limits the generalizability of our 830 findings to other populations. It is crucial to conduct cross-ancestry follow-up studies to 831 determine whether these results hold across diverse ethnic groups. Overcoming these 832 limitations will require enhancing the diversity of GWAS populations and conducting 833 more extensive experimental validations and cohort analyses.

834

835 Conclusion

836 Together, this study has significantly improved our understanding of the genetic basis 837 for the role of eGFR in susceptibility to major CVDs. By identifying crucial genetic 838 components, including key pleiotropic loci and genes such as L3MBTL3, MMP24, and 839 ABO, we elucidate potential shared mechanisms that may influence critical biological 840 pathways associated with CVDs, notably stem cell population maintenance and 841 glutathione metabolism. These results provide a better understanding of the genetic 842 basis of CVDs and provide a basis for the development of more targeted therapeutic 843 and preventive strategies that could potentially transform cardiovascular care.

844

845 Disclosure

- All authors declare no competing interests.
- 847

848 Data Statement

The study used only openly available GWAS summary statistics on estimated glomerular filtration rate and six major cardiovascular diseases that have originally been conducted using human data. GWAS summary statistics on eGFR are available at

852 https://www.uni-regensburg.de/medizin/epidemiologie-praeventivmedizin/

853	genetische-epidemiologie/gwas-summary-statistics/index.html. GWAS summary
854	statistics on AF, HF, and Stroke are available at the GWAS Catalog (GCST90104539,
855	GCST009541, and GCST90104539). GWAS summary statistics on CAD and PAD are
856	publicly available for download at the Cardiovascular Disease Knowledge Portal
857	(CVDKP) website: https://cvd.hugeamp.org/datasets.html. GWAS summary statistics
858	on VTE are obtained from the deCODE genetics website: https://www.decode.com/
859	summarydata/. Blood-based cis-pQTL from UKB-PPP are obtained from
860	https://www.synapse.org/Synapse:syn51365303.

861

862 Acknowledgements

863 This study was supported by the Natural Science Foundation of China Excellent Young 864 Scientists Fund (Overseas) (Grant no. K241141101), Guangdong Basic and Applied 865 Basic Research Foundation for Distinguished Young Scholars (Grant no. 866 24050000763), Shenzhen Pengcheng Peacock Plan, Shenzhen Basic Research General 867 Projects of Shenzhen Science and Technology Innovation Commission (Grant no. JCYJ20230807093514029) (To Y.F.), National Natural Science Foundation of China 868 869 (Grant no. 82260073); Tianshan Talent Cultivation Program Project of Xinjiang Uygur 870 Autonomous Region (Grant no. 2022TSYCLJ0028) (To Y.Y.), and Center for 871 Computational Science and Engineering at Southern University of Science and 872 Technology. The funder had no role in the design, implementation, analysis, 873 interpretation of the data, approval of the manuscript, and decision to submit the

874 manuscript for publication.

875

876 Author contributions

- 877 J.Q., Y. F., Y.Y., J.X., and S.P. conceptualized and supervised this project and wrote the
- 878 manuscript. J.Q., K.Y., and Y.Y. performed the main analyses and wrote the manuscript.
- 879 J.Q., X.Y., Y.Y., L.Z., and Y.L. performed the statistical analysis and assisted with
- 880 interpreting the results. M.C., W.X., and Y.Y. provided expertise in cardiovascular
- biology and GWAS summary statistics. All authors provided intellectual content and
- approved the final version of the manuscript.

883

884 **Reference**

- Roth, G. A. et al. Global, Regional, and National Burden of Cardiovascular
 Diseases for 10 Causes, 1990 to 2015. Journal of the American College of
 Cardiology 70, 1-25, doi:10.1016/j.jacc.2017.04.052 (2017).
- Bays, H. E. et al. Ten things to know about ten cardiovascular disease risk
 factors. American journal of preventive cardiology 5, 100149,
 doi:10.1016/j.ajpc.2021.100149 (2021).
- 891 3. Popolo, A., Autore, G., Pinto, A. & Marzocco, S. Oxidative stress in patients
 892 with cardiovascular disease and chronic renal failure. Free radical research 47,
 893 346-356, doi:10.3109/10715762.2013.779373 (2013).
- 4. Ammirati, A. L. Chronic Kidney Disease. Revista da Associacao Medica
 Brasileira (1992) 66Suppl 1, s03-s09, doi:10.1590/1806-9282.66.S1.3 (2020).
- Eckardt, K. U. et al. Evolving importance of kidney disease: from subspecialty
 to global health burden. Lancet (London, England) 382, 158-169,
 doi:10.1016/s0140-6736(13)60439-0 (2013).
- 899 6. Visseren, F. L. J. et al. 2021 ESC Guidelines on cardiovascular disease
 900 prevention in clinical practice. European journal of preventive cardiology 29,
 901 5-115, doi:10.1093/eurjpc/zwab154 (2022).
- P02 7. Lees, J. S. et al. Glomerular filtration rate by differing measures, albuminuria
 p03 and prediction of cardiovascular disease, mortality and end-stage kidney
 p04 disease. Nat Med 25, 1753-1760, doi:10.1038/s41591-019-0627-8 (2019).
- 8. Manjunath, G. et al. Level of kidney function as a risk factor for cardiovascular
 outcomes in the elderly. Kidney international 63, 1121-1129,
 doi:10.1046/j.1523-1755.2003.00838.x (2003).
- 908 9. Ataklte, F. et al. Association of Mildly Reduced Kidney Function With
 909 Cardiovascular Disease: The Framingham Heart Study. Journal of the American
 910 Heart Association 10, e020301, doi:10.1161/jaha.120.020301 (2021).
- 911 10. Graham, S. E. et al. Sex-specific and pleiotropic effects underlying kidney
 912 function identified from GWAS meta-analysis. Nature communications 10,
 913 1847, doi:10.1038/s41467-019-09861-z (2019).

11. Kelly, D. M. et al. Interplay Between Chronic Kidney Disease, Hypertension,

and Stroke: Insights From a Multivariable Mendelian Randomization Analysis.

916 Neurology 101, e1960-e1969, doi:10.1212/wnl.000000000207852 (2023).

- 917 12. Geurts, S. et al. Disentangling the association between kidney function and
 918 atrial fibrillation: a bidirectional Mendelian randomization study. International
 919 journal of cardiology 355, 15-22, doi:10.1016/j.ijcard.2022.03.004 (2022).
- Park, S. et al. Atrial fibrillation and kidney function: a bidirectional Mendelian
 randomization study. Eur Heart J 42, 2816-2823,
 doi:10.1093/eurheartj/ehab291 (2021).
- 923 14. Gong, W. et al. Role of the Gut-Brain Axis in the Shared Genetic Etiology
 924 Between Gastrointestinal Tract Diseases and Psychiatric Disorders: A
 925 Genome-Wide Pleiotropic Analysis. JAMA psychiatry 80, 360-370,
 926 doi:10.1001/jamapsychiatry.2022.4974 (2023).
- 927 15. Stanzick, K. J. et al. Discovery and prioritization of variants and genes for
 928 kidney function in >1.2 million individuals. Nature communications 12, 4350,
 929 doi:10.1038/s41467-021-24491-0 (2021).
- 930 16. Nielsen, J. B. et al. Biobank-driven genomic discovery yields new insight into
 931 atrial fibrillation biology. Nature genetics 50, 1234-1239,
 932 doi:10.1038/s41588-018-0171-3 (2018).
- Aragam, K. G. et al. Discovery and systematic characterization of risk variants
 and genes for coronary artery disease in over a million participants. Nature
 genetics 54, 1803-1815, doi:10.1038/s41588-022-01233-6 (2022).
- 936 18. Ghouse, J. et al. Genome-wide meta-analysis identifies 93 risk loci and enables
 937 risk prediction equivalent to monogenic forms of venous thromboembolism.
 938 Nature genetics 55, 399-409, doi:10.1038/s41588-022-01286-7 (2023).
- 939 19. Shah, S. et al. Genome-wide association and Mendelian randomisation analysis
 940 provide insights into the pathogenesis of heart failure. Nature communications
 941 11, 163, doi:10.1038/s41467-019-13690-5 (2020).
- 942 20. van Zuydam, N. R. et al. Genome-Wide Association Study of Peripheral Artery
 943 Disease. Circulation. Genomic and precision medicine 14, e002862,

944 doi:10.1161/circgen.119.002862 (2021).

- 945 21. Mishra, A. et al. Stroke genetics informs drug discovery and risk prediction
 946 across ancestries. Nature 611, 115-123, doi:10.1038/s41586-022-05165-3
 947 (2022).
- 948 22. Bulik-Sullivan, B. K. et al. LD Score regression distinguishes confounding
 949 from polygenicity in genome-wide association studies. Nature genetics 47,
 950 291-295, doi:10.1038/ng.3211 (2015).
- 951 23. Hindley, G. et al. Charting the Landscape of Genetic Overlap Between Mental
 952 Disorders and Related Traits Beyond Genetic Correlation. The American
 953 journal of psychiatry 179, 833-843, doi:10.1176/appi.ajp.21101051 (2022).
- Werme, J., van der Sluis, S., Posthuma, D. & de Leeuw, C. A. An integrated
 framework for local genetic correlation analysis. Nature genetics 54, 274-282,
 doi:10.1038/s41588-022-01017-y (2022).
- 957 25. Darrous, L., Mounier, N. & Kutalik, Z. Simultaneous estimation of
 958 bi-directional causal effects and heritable confounding from GWAS summary
 959 statistics. Nature communications 12, 7274, doi:10.1038/s41467-021-26970-w
 960 (2021).
- 961 26. Ray, D. & Chatterjee, N. A powerful method for pleiotropic analysis under
 962 composite null hypothesis identifies novel shared loci between Type 2 Diabetes
 963 and Prostate Cancer. PLoS genetics 16, e1009218,
 964 doi:10.1371/journal.pgen.1009218 (2020).
- Watanabe, K., Taskesen, E., van Bochoven, A. & Posthuma, D. Functional
 mapping and annotation of genetic associations with FUMA. Nature
 communications 8, 1826, doi:10.1038/s41467-017-01261-5 (2017).
- 968 28. Kircher, M. et al. A general framework for estimating the relative pathogenicity
 969 of human genetic variants. Nature genetics 46, 310-315, doi:10.1038/ng.2892
 970 (2014).
- 971 29. Boyle, A. P. et al. Annotation of functional variation in personal genomes using
 972 RegulomeDB. Genome research 22, 1790-1797, doi:10.1101/gr.137323.112
 973 (2012).

- 974 30. Kundaje, A. et al. Integrative analysis of 111 reference human epigenomes.
- 975 Nature 518, 317-330, doi:10.1038/nature14248 (2015).
- 976 31. Zhu, Z. et al. Integration of summary data from GWAS and eQTL studies
 977 predicts complex trait gene targets. Nature genetics 48, 481-487,
 978 doi:10.1038/ng.3538 (2016).
- Wallace, C. A more accurate method for colocalisation analysis allowing for
 multiple causal variants. PLoS genetics 17, e1009440,
 doi:10.1371/journal.pgen.1009440 (2021).
- 982 33. van der Linden, R. J. et al. Genetic overlap between Alzheimer's disease and
 983 blood lipid levels. Neurobiology of aging 108, 189-195,
 984 doi:10.1016/j.neurobiolaging.2021.06.019 (2021).
- 985 34. de Leeuw, C. A., Mooij, J. M., Heskes, T. & Posthuma, D. MAGMA:
 986 generalized gene-set analysis of GWAS data. PLoS computational biology 11,
 987 e1004219, doi:10.1371/journal.pcbi.1004219 (2015).
- 35. Gerring, Z. F., Mina-Vargas, A., Gamazon, E. R. & Derks, E. M. E-MAGMA:
 an eQTL-informed method to identify risk genes using genome-wide
 association study summary statistics. Bioinformatics (Oxford, England) 37,
 2245-2249, doi:10.1093/bioinformatics/btab115 (2021).
- 36. Gusev, A. et al. Integrative approaches for large-scale transcriptome-wide
 association studies. Nature genetics 48, 245-252, doi:10.1038/ng.3506 (2016).
- 37. Zhou, Y. et al. Metascape provides a biologist-oriented resource for the analysis
 of systems-level datasets. Nature communications 10, 1523,
 doi:10.1038/s41467-019-09234-6 (2019).
- 38. Levy, D. et al. Genome-wide association study of blood pressure and
 hypertension. Nature genetics 41, 677-687, doi:10.1038/ng.384 (2009).
- 39. Yamada, Y. et al. Identification of 13 novel susceptibility loci for early-onset
 myocardial infarction, hypertension, or chronic kidney disease. International
 journal of molecular medicine 42, 2415-2436, doi:10.3892/ijmm.2018.3852
 (2018).
- 1003 40. Liu, C. et al. STUB1 is acetylated by KAT5 and alleviates myocardial

- 1004 ischemia-reperfusion injury through LATS2-YAP- β -catenin axis. 1005 Communications biology 7, 396, doi:10.1038/s42003-024-06086-9 (2024).
- Hishikawa, A. et al. DNA repair factor KAT5 prevents ischemic acute kidney
 injury through glomerular filtration regulation. iScience 24, 103436,
 doi:10.1016/j.isci.2021.103436 (2021).
- Cano, E. A. et al. Association between ABO Blood Groups and Type 2 Diabetes
 Mellitus: A Meta-Analysis. Curr Diabetes Rev 19, e270422204139,
 doi:10.2174/1573399818666220427124448 (2023).
- Yuan, S., Bruzelius, M. & Larsson, S. C. Causal effect of renal function on venous thromboembolism: a two-sample Mendelian randomization investigation. Journal of thrombosis and thrombolysis 53, 43-50, doi:10.1007/s11239-021-02494-4 (2022).
- Watanabe, H. et al. Close bidirectional relationship between chronic kidney
 disease and atrial fibrillation: the Niigata preventive medicine study. American
 heart journal 158, 629-636, doi:10.1016/j.ahj.2009.06.031 (2009).
- Kim, J. J. et al. Identification of B-cell-related HSPG2 and CDSN as
 susceptibility loci for Kawasaki disease. Human immunology 84, 567-570,
 doi:10.1016/j.humimm.2023.07.001 (2023).
- 1022 46. Newburger, J. W. et al. Diagnosis, treatment, and long-term management of
 1023 Kawasaki disease: a statement for health professionals from the Committee on
 1024 Rheumatic Fever, Endocarditis and Kawasaki Disease, Council on
 1025 Cardiovascular Disease in the Young, American Heart Association. Circulation
 1026 110, 2747-2771, doi:10.1161/01.Cir.0000145143.19711.78 (2004).
- 47. Sallinen, R. et al. Association of the SLC22A1, SLC22A2, and SLC22A3 genes
 encoding organic cation transporters with diabetic nephropathy and
 hypertension. Annals of medicine 42, 296-304,
 doi:10.3109/07853891003777109 (2010).
- 48. Garcia-Fernandez, N. et al. Matrix Metalloproteinases in Diabetic Kidney
 Disease. Journal of clinical medicine 9, doi:10.3390/jcm9020472 (2020).
- 1033 49. Chen, S., Chen, L. & Jiang, H. Prognosis and risk factors of chronic kidney

1034 disease progression in patients with diabetic kidney disease and non-diabetic

1035 kidney disease: a prospective cohort CKD-ROUTE study. Renal failure 44,

1036 1309-1318, doi:10.1080/0886022x.2022.2106872 (2022).

- 1037 50. Zhang, H., Mooney, C. J. & Reilly, M. P. ABO Blood Groups and
 1038 Cardiovascular Diseases. Int J Vasc Med 2012, 641917,
 1039 doi:10.1155/2012/641917 (2012).
- Wang, M. et al. Associations of ABO blood type and galactose-deficient
 immunoglobulin A1 with adverse outcomes in patients with IgA nephropathy.
 Nephrology, dialysis, transplantation : official publication of the European
 Dialysis and Transplant Association European Renal Association 36, 288-294,
 doi:10.1093/ndt/gfz171 (2021).
- 1045 52. Porlan, E. et al. MT5-MMP regulates adult neural stem cell functional
 1046 quiescence through the cleavage of N-cadherin. Nature cell biology 16, 629-638,
 1047 doi:10.1038/ncb2993 (2014).
- 1048 53. Wilson, N. K. et al. Combined Single-Cell Functional and Gene Expression
 1049 Analysis Resolves Heterogeneity within Stem Cell Populations. Cell stem cell
 1050 16, 712-724, doi:10.1016/j.stem.2015.04.004 (2015).
- 1051 54. Coulter, M. E. et al. The ESCRT-III Protein CHMP1A Mediates Secretion of
 1052 Sonic Hedgehog on a Distinctive Subtype of Extracellular Vesicles. Cell reports
 1053 24, 973-986.e978, doi:10.1016/j.celrep.2018.06.100 (2018).
- 1054 55. Hopkins, C., Li, J., Rae, F. & Little, M. H. Stem cell options for kidney disease.
 1055 J Pathol 217, 265-281, doi:10.1002/path.2477 (2009).
- 56. Strauer, B. E. & Steinhoff, G. 10 years of intracoronary and intramyocardial
 bone marrow stem cell therapy of the heart: from the methodological origin to
 clinical practice. Journal of the American College of Cardiology 58, 1095-1104,
 doi:10.1016/j.jacc.2011.06.016 (2011).
- 1060 57. Lau, A. et al. Dipeptidase-1 governs renal inflammation during ischemia
 1061 reperfusion injury. Science advances 8, eabm0142,
 1062 doi:10.1126/sciadv.abm0142 (2022).
- 1063 58. Wu, J. et al. Regulation of the urea cycle by CPS1 O-GlcNAcylation in response

to dietary restriction and aging. Journal of molecular cell biology 14,
doi:10.1093/jmcb/mjac016 (2022).

- 1066 59. Matuz-Mares, D., Riveros-Rosas, H., Vilchis-Landeros, M. M. & V á
 1067 zquez-Meza, H. Glutathione Participation in the Prevention of Cardiovascular
 1068 Diseases. Antioxidants (Basel, Switzerland) 10, doi:10.3390/antiox10081220
 1069 (2021).
- 1070 60. Bajic, V. P. et al. Glutathione "Redox Homeostasis" and Its Relation to
 1071 Cardiovascular Disease. Oxidative medicine and cellular longevity 2019,
 1072 5028181, doi:10.1155/2019/5028181 (2019).
- 107361.Hinchman, C. A. & Ballatori, N. Glutathione-degrading capacities of liver and1074kidney in different species. Biochemical pharmacology 40, 1131-1135,
- 1075 doi:10.1016/0006-2952(90)90503-d (1990).

1076



1077

Figure 1: Schematic diagram of the analysis of genetic associations between glomerular filtration rate and six major cardiovascular diseases in this study.

We analyzed the most comprehensive GWAS summary statistics to investigate the shared genetic architecture and potential mechanisms between eGFR and CVDs. First, the shared genetic basis was determined by quantifying global and local genetic correlations and exploring the global genetic overlap. Then, their two genetic pleiotropy were analyzed to investigate the shared genetic

1084	architecture, which can be vertical pleiotropy, that is, the effect of the variant on one trait affects
1085	another trait or horizontal pleiotropy, that is, the variant affects multiple traits independently. We
1086	first used Mendelian randomization on vertical pleiotropy to illustrate their causal relationship.
1087	Then, various statistical genetic methods were used on horizontal pleiotropy to sequentially apply
1088	pleiotropy analysis at the SNP, gene level, biological pathway, and protein target level to investigate
1089	the common genetic mechanism. Through this comprehensive genetic pleiotropy analysis, our
1090	understanding of the genetic link between eGFR and CVDs has been dramatically enhanced, which
1091	may guide the development of new treatment strategies and improve the clinical management of
1092	these diseases.





Figure 2: Genetic overlap between estimated glomerular filtration rate and six major
cardiovascular diseases exceeds genome-wide genetic correlation.

1096 Genetic overlap and local genetic correlation between eGFR and six major CVDs investigated by1097 MiXeR and LAVA. a: MiXeR Venn diagrams showing common and unique effect trait variants

1098	showing polygenic overlap (grey) between eGFR (blue) and CVDs (orange). Numbers in the Venn
1099	diagrams indicate the estimated number of common and unique effect trait variants (in thousands)
1100	that explain 90% of the SNP heritability and standard error in each phenotype. Circle size indicates
1101	the degree of polygenicity for each trait, with larger circles indicating stronger polygenicity. We also
1102	provide genome-wide genetic correlation (r_g) and genetic correlation of shared variants $(r_g s)$. b:
1103	LAVA volcano plots showing local genetic correlation coefficients (local- r_gs , y-axis) for eGFR and
1104	CVDs with -log10 <i>p</i> -values for each trait pair of analyses for each locus. Loci above the horizontal
1105	line are significant at $P < 0.05$ (negative correlation for blue dots, positive correlation for red dots).
1106	Larger points with black circles indicate loci significantly associated after Bonferroni correction (P
1107	$< 0.05 / 425$). LAVA-estimated local- $r_g s$ is shown on the blue-red scale. eGFR, estimated glomerular
1108	filtration rate; AF, atrial fibrillation; CAD, coronary artery disease; VTE, venous thromboembolism;
1109	HF, heart failure; PAD, peripheral arterial disease.

1110





Figure 3: Inference of causal relationship between estimated glomerular filtration rate and six
major cardiovascular diseases.

Forest plots of the causal relationship between eGFR and six major CVDs using the LHC-MR method. a: indicates the estimated causal relationship of eGFR on CVDs. b: indicates the estimated causal relationship of CVDs on eGFR. Circles indicate odds ratio (OR) estimates, and error bars indicate 95% confidence intervals. OR > 1 indicates a positive association, and OR < 1 indicates a negative association. eGFR, estimated glomerular filtration rate; AF, atrial fibrillation; CAD, coronary artery disease; VTE, venous thromboembolism; HF, heart failure; PAD, peripheral arterial disease.



1121



1124 Manhattan plots reflect chromosomal position (x-axis) and negative log10-transformed P-values 1125 (y-axis) for each SNP. Horizontal lines indicate genome-wide significant P-values $-\log 10 (5 \times 10^{-8})$. The r^2 threshold for defining independent significant SNPs was set to 0.2, and the maximum 1126 1127 distance between LD blocks merged into one locus was set to 500 kb. P-values were derived using 1128 GWAS multi-trait analysis in discovery studies, and independent genome-wide significant 1129 associations with the smallest P-values (top SNPs) are circled in colored circles. Only SNPs that 1130 were common in all summary statistics were included. Labels are chromosomal regions where 1131 genomic risk loci with strong colocalization evidence (PP.H4 > 0.7) are located. eGFR, estimated 1132 glomerular filtration rate; AF, atrial fibrillation; CAD, coronary artery disease; VTE, venous 1133 thromboembolism; HF, heart failure; PAD, peripheral arterial disease.



1134

Figure 5: The overall situation of the pleiotropy association between estimated glomerular filtration rate and six major cardiovascular diseases

1137 Based on the polygenic nature of the Mixer results, we separated the pleiotropic association between 1138 eGFR and CVDs into two network diagrams, showing the pleiotropic loci and genes identified in 1139 the six trait pairs. a: The circular dendrogram is centered on eGFR (inner circle) and branches out 1140 for the three CVDs (second circle, AF, VTE, and PAD). These three trait pairs show 91 pleiotropic 1141 loci (third circle) corresponding to 159 pleiotropic genes (outer circle). b: The circular dendrogram 1142 is centered on eGFR (the inner circle) and branches out for the three CVDs (second circle, CAD, HF, 1143 and stroke). Another three trait pairs show 80 pleiotropic loci (third circle) corresponding to 153 1144 pleiotropic genes (outer circle). For trait pairs with three or more pleiotropic genes, we only show 1145 the top three pleiotropic genes according to priority, and these genes show statistical priority decay 1146 in clockwise direction. For example, eGFR-AF-12q24.31-CCDC92 and а 1147 eGFR-AF-12q24.31-ZNF664 indicate that 12q24.31 is a shared locus for this pair of specific 1148 diseases involving CCDC92 and ZNF664. eGFR, estimated glomerular filtration rate; AF, atrial 1149 fibrillation; CAD, coronary artery disease; VTE, venous thromboembolism; HF, heart failure; PAD, 1150 peripheral arterial disease.